Loading…
Loading…
SAVA (Cassava Sciences, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SAVA and 80,000+ other tickers.
See exactly how SAVA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SAVA and 80,000+ other tickers.
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders.
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agreement to resolve the previously disclosed consolidated securities class action litigation pending in the United States District Court for the Western District of Texas Austin Division (In re Cassava Sciences, Inc. Securities Litigation, No. 1:21-cv-00751-DAE) (the “Consolidated Securities Action”). This lawsuit was originally filed in 2021.
Cassava Sciences Inc. (NASDAQ: SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company's trial for simufilam
Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Cassava Sciences (NASDAQ: SAVA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Institutional and Insider Ownership 44.3% of Carisma
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders. If you currently own Cassava stock and acquired shares on or before September 14, 2020, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to l.